The legendary billionaire macro trader, Stanley Druckenmiller, has built his career on a simple habit. When he finds a bet he believes in, he sizes it big and watches it closely.
Right now, that bet is a cancer-testing company most people have never heard of: Natera (NTRA), and the reason he keeps buying tells you something useful about where he thinks healthcare is going.
His family office holds more of it than any other stock, and he added to the position last quarter even as the shares traded near record highs.
What Druckenmiller’s Natera bet actually looks like right now
Druckenmiller runs his money through the Duquesne Family Office, and his stock holdings show up every quarter in a public filing called a 13F.
A 13F is a report that large investors must file with the Securities and Exchange Commission, listing the U.S. stocks they own.
His most recent filing, dated August 14, 2026, covers the second quarter and shows Natera as his single largest holding at 16.6% of the reported portfolio, according to the SEC filing.
More Healthcare Stocks:
- Federal court hands Gilead a win that protects its top HIV drug
- BofA biotech scorecard: Two buys and odd one out
- Lilly gains access to market that could add millions of customers
That’s worth about $864.9 million.
He did not just hold the position. He added 122,700 shares during the quarter, lifting the stake to about 3.19 million shares.
That detail matters, because the stock was expensive at the time. He kept buying anyway.
Why a macro trader put so much into one healthcare stock
Druckenmiller made his name betting on currencies, interest rates, and big economic shifts, not on individual biotech companies.
So a concentrated Natera position looks unusual on the surface.
The logic becomes clearer when you look at what Natera sells.
Its main product is Signatera, a blood test that looks for tiny fragments of tumor DNA left in the body after cancer treatment.
Doctors use it to catch a cancer coming back earlier than a scan would show.
That is a service hospitals order regardless of the economy. A patient monitored for cancer recurrence gets tested whether interest rates rise or fall.
For an investor who spends his days worrying about the economy, a business that keeps selling through a downturn is rare.
How Natera’s latest results support the thesis
The numbers behind the bet are strong.
Natera reported second-quarter revenue of $752.8 million on August 6, 2026, up 37.7% from a year earlier.
That beat Wall Street’s estimate of about $662.6 million.
The company processed more than one million tests for the second quarter in a row, and oncology test volume jumped 57.2%.
Here is what stood out in the quarter:
Natera second-quarter 2026 highlights
- Revenue of $752.8 million, up 37.7% from a year earlier, beating expectations.
- Oncology testing volume up 57.2%, driven by Signatera.
- Gross margin of 64.5%, up from 63.4% a year earlier.
- Full-year revenue guidance raised to a range of $2.85 billion to $2.91 billion.
- Net loss narrowed to 47 cents a share from 74 cents a year earlier.
Natera still loses money, but the loss is shrinking, and management now expects positive cash flow for the full year.
The part of the bet that most investors miss
The peculiar part of Druckenmiller’s position is not that he owns Natera. It is how much he owns relative to everything else.
His second-largest holding, drugmaker Insmed, sits at 5.7% of the portfolio. Natera is nearly three times that size.
Related: Morgan Stanley uncovers major Bristol Myers stock signals
He has said before that he prefers to concentrate when conviction is high, once describing his approach as putting his eggs in one basket and watching the basket closely.
Making a mid-sized cancer-testing company his top holding, ahead of every large technology name, shows he treats Natera’s growth as close to a sure thing rather than a gamble.
That conviction is the signal retail investors should focus on, more than the exact share count.
What this means if you are already holding Natera
A large, patient owner like Duquesne can steady a stock.
When a well-known investor holds millions of shares and keeps adding, it becomes harder for short sellers to push the price down without pushback.
Druckenmiller’s presence also sends a message about what to watch. He is backing revenue growth and rising test volumes, not quarterly profit.
If you own Natera, what matters most are test volume growth, Signatera adoption, and progress toward positive cash flow, rather than whether the company posts a net profit next quarter.
What to check before buying Natera today
If you are thinking about buying, the timing of Druckenmiller’s filing is the first thing to understand.
A 13F can be released up to 45 days after a quarter ends, so it shows where an investor stood in the past, not where they stand today.
Druckenmiller bought his shares during the second quarter, when Natera traded well below its recent levels.
The stock closed at $311.69 on August 18, 2026, up about 36% for the year and near its 52-week high of $326.03.
Buying now means paying a much higher price than he did.
A few risks are worth weighing before you follow him:
- Natera trades at a high price relative to sales, so any slowdown in test growth could hit the stock hard.
- The company depends on insurers and Medicare paying for its tests, and reimbursement rules can change.
- Competition in cancer-recurrence testing is increasing, even though Natera leads today.
The bottom line for investors
Druckenmiller’s Natera position is a clear, high-conviction bet on cancer diagnostics as a business that grows through any economy.
The company’s second-quarter results back that view, with revenue up 37.7%, record test volumes, and raised guidance.
Related: Key HIV stat over 70% leaves BofA siding with Gilead
For current shareholders, his continued buying is a reason to focus on volume and cash flow rather than short-term losses.
For prospective buyers, it is better to be more cautious. The stock is up about 36% this year and sits near a record, so the easy entry point Druckenmiller got is gone.
Size any position to your own risk tolerance and watch Signatera volume growth and reimbursement decisions in the coming quarters.
This is not investment advice, and a single investor’s holdings should never be the only reason to buy a stock.
